Ro
Ro raises $500M Series D at $5B valuation
Quick Facts
Ro: Series D Funding Round
Ro has successfully raised $500M in Series D funding, reaching a valuation of $5B.
Company Overview
Direct-to-patient healthcare platform
Funding Details
The Series D round was led by General Catalyst, with participation from TCV.
Company Information
- Headquarters: New York, NY
- Founded: 2017
- Employees: 800+
- Category: HealthTech
Investment
Ro plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- General Catalyst: Verified investor in Series D
- TCV: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
